Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

BRIEF-Aurinia reports Q4 net loss of 13 cents per common share

Published 2016-03-18, 05:47 p/m
© Reuters.  BRIEF-Aurinia reports Q4 net loss of 13 cents per common share
AUPH
-

March 18 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* Reports fourth quarter and full year 2015 financial results and recent
operational highlights
* Expects that the primary end-point results of the aura trial will be released
in the third quarter ended September 30, 2016
* Reported a consolidated net loss of $4.1 million or $0.13 per common share
for the three months ended December 31, 2015
* Pharma - believes financial resources should be sufficient to finance aura
trial, aurion study, corporate costs until about December 31, 2016
* Qtrly loss per share $0.13
* Future cash requirements could vary from current estimates due to number of
factors including costs associated with aura trial
* Q4 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

* Source text for Eikon ID:nBw5nDr0ga

* Further company coverage AUP.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.